217 related articles for article (PubMed ID: 36116215)
41. Deciphering the tumor microenvironment cell-infiltrating landscape reveals microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC.
Chen H; Zhang T; Zhang Y; Wu H; Fang Z; Liu Y; Chen Y; Wang Z; Jia S; Ji X; Shang L; Du F; Liu J; Lu M; Chong W
JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35511432
[TBL] [Abstract][Full Text] [Related]
42. N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer.
Zhang H; Kong W; Zhao X; Han C; Liu T; Li J; Song D
BMC Genom Data; 2022 Jan; 23(1):8. PubMed ID: 35042477
[TBL] [Abstract][Full Text] [Related]
43. Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy.
Yu H; Liu J; Bu X; Ma Z; Yao Y; Li J; Zhang T; Song W; Xiao X; Sun Y; Xiong W; Shi J; Dai P; Xiang B; Duan H; Yan X; Wu F; Zhang WC; Lin D; Hu H; Zhang H; Slack FJ; He HH; Freeman GJ; Wei W; Zhang J
Cell Chem Biol; 2024 Apr; 31(4):776-791.e7. PubMed ID: 37751743
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive Analysis of Clinical Significance, Immune Infiltration and Biological Role of m
Zhou B; Gao S
Front Immunol; 2021; 12():698236. PubMed ID: 34650549
[TBL] [Abstract][Full Text] [Related]
45. m
Chong W; Shang L; Liu J; Fang Z; Du F; Wu H; Liu Y; Wang Z; Chen Y; Jia S; Chen L; Li L; Chen H
Theranostics; 2021; 11(5):2201-2217. PubMed ID: 33500720
[TBL] [Abstract][Full Text] [Related]
46. Human Mitochondrial Ribosomal RNA Modification-Based Classification Contributes to Discriminate the Prognosis and Immunotherapy Response of Glioma Patients.
Wang P; Li J; Wu M; Ye M; Huang K; Zhu X
Front Immunol; 2021; 12():722479. PubMed ID: 34566979
[TBL] [Abstract][Full Text] [Related]
47. Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing.
Yang L; Wei S; Zhang J; Hu Q; Hu W; Cao M; Zhang L; Wang Y; Wang P; Wang K
J Transl Med; 2022 Aug; 20(1):364. PubMed ID: 35962453
[TBL] [Abstract][Full Text] [Related]
48. Interplay of four types of RNA modification writers revealed distinct tumor microenvironment and biological characteristics in pancreatic cancer.
Gao W; Chen D; Liu J; Zang L; Xiao T; Zhang X; Li Z; Zhu H; Yu X
Front Immunol; 2022; 13():1031184. PubMed ID: 36601127
[TBL] [Abstract][Full Text] [Related]
49. Analysis between macrophage-related genes with prognosis and tumor microenvironment in non-small cell lung cancer.
Sun QY; Zhou Y; Du LJ; Zhang MK; Wang JL; Ren YY; Liu F
Yi Chuan; 2023 Aug; 45(8):684-699. PubMed ID: 37609819
[TBL] [Abstract][Full Text] [Related]
50. Machine learning-identified stemness features and constructed stemness-related subtype with prognosis, chemotherapy, and immunotherapy responses for non-small cell lung cancer patients.
Liu M; Zhou R; Zou W; Yang Z; Li Q; Chen Z; Jiang L; Zhang J
Stem Cell Res Ther; 2023 Sep; 14(1):238. PubMed ID: 37674202
[TBL] [Abstract][Full Text] [Related]
51. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
52. m
Yuan B; Qin H; Zhang J; Zhang M; Yang Y; Teng X; Yu H; Huang W; Wang Y
Front Oncol; 2022; 12():1087753. PubMed ID: 36591468
[TBL] [Abstract][Full Text] [Related]
53. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
54. Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non-small cell lung cancer.
Deng J; Ma X; Ni Y; Li X; Xi W; Tian M; Zhang X; Xiang M; Deng W; Song C; Wu H
Cancer Med; 2022 Apr; 11(8):1787-1795. PubMed ID: 35150082
[TBL] [Abstract][Full Text] [Related]
55. Tumor microenvironment(TME) and single-source dual-energy CT(ssDECT) on assessment of inconformity between RECIST1.1 and pathological remission in neoadjuvant immunotherapy of NSCLC.
Sun C; Ma X; Meng F; Chen X; Wang X; Sun W; Xu Y; He H; Zhang H; Ma K
Neoplasia; 2024 Apr; 50():100977. PubMed ID: 38354688
[TBL] [Abstract][Full Text] [Related]
56. [Comprehensive Analysis of the Relationship between m6A Methylation Patterns and Immune Microenvironment in Lung Adenocarcinoma].
Ke J; Cui J; Yang X; Du X; Ma B; Yu L
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):311-322. PubMed ID: 35599007
[TBL] [Abstract][Full Text] [Related]
57. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
Front Immunol; 2022; 13():974581. PubMed ID: 36159860
[TBL] [Abstract][Full Text] [Related]
58. RNA N
Zhang Z; Zhang C; Luo Y; Zhang G; Wu P; Sun N; He J
Clin Transl Med; 2021 Sep; 11(9):e525. PubMed ID: 34586737
[TBL] [Abstract][Full Text] [Related]
59. m
Sun M; Xie M; Zhang T; Wang Y; Huang W; Xia L
Front Immunol; 2021; 12():739768. PubMed ID: 34616403
[TBL] [Abstract][Full Text] [Related]
60. Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.
Pircher A; Gamerith G; Amann A; Reinold S; Popper H; Gächter A; Pall G; Wöll E; Jamnig H; Gastl G; Wolf AM; Hilbe W; Wolf D
Lung Cancer; 2014 Jul; 85(1):81-7. PubMed ID: 24780112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
